PMID- 38189220
OWN - NLM
STAT- MEDLINE
DCOM- 20240109
LR  - 20240117
IS  - 1651-2057 (Electronic)
IS  - 0001-5555 (Print)
IS  - 0001-5555 (Linking)
VI  - 104
DP  - 2024 Jan 8
TI  - Solar Urticaria: An Ambispective Study in a Long-term Follow-up Cohort with 
      Emphasis on Therapeutic Predictors and Outcomes.
PG  - adv25576
LID - 10.2340/actadv.v104.25576 [doi]
LID - 25576
AB  - Solar urticaria is a rare photodermatosis with several unknown pathogenic, 
      clinical and therapeutic aspects. This study analysed the clinical and 
      therapeutic features of a long-term follow-up solar urticaria cohort, with a 
      focus on omalizumab management and outcomes, and characterized omalizumab 
      response with the use of the high-affinity immunoglobulin E (IgE) receptor 
      (FcepsilonRI) and the Urticaria Control Test. An observational, unicentric, 
      ambispective study was conducted from 2007 to 2023. Solar urticaria was diagnosed 
      in 41 patients with a median follow-up of 60 months. Thirteen patients were 
      prescribed omalizumab, with a median treatment time of 48 months. A significant 
      decrease in FcepsilonRI baseline levels and subsequent median increase in Urticaria 
      Control Test was evidenced after omalizumab prescription in all patients. Drug 
      survival at 48 months was at 88.9%. Omalizumab stepping-down protocol led to 
      sustained omalizumab discontinuation in only 1 patient. Median basal Urticaria 
      Control Test was lower (p < 0.01) in patients who were prescribed omalizumab and 
      in patients without remission. This study contributes to our knowledge of 
      omalizumab outcomes in real-life clinical practice and highlights the pathogenic 
      importance of IgE-mediated pathways in solar urticaria, where FcepsilonRI emerges as a 
      possible biomarker of omalizumab response.
FAU - Pesque, David
AU  - Pesque D
AD  - Department of Dermatology, Hospital del Mar Research Institute, Department of 
      Medicine, Autonomous University of Barcelona/Universitat Autonoma de Barcelona 
      (UAB), Barcelona, Spain.
FAU - Ciudad, Andrea
AU  - Ciudad A
AD  - Department of Dermatology, Hospital del Mar Research Institute, Barcelona, Spain.
FAU - Andrades, Evelyn
AU  - Andrades E
AD  - Department of Immunology, IMIM Hospital del Mar Research Institute, Barcelona, 
      Spain.
FAU - Soto, Dulce
AU  - Soto D
AD  - Department of Immunology, IMIM Hospital del Mar Research Institute, Barcelona, 
      Spain.
FAU - Gimeno, Ramon
AU  - Gimeno R
AD  - DDepartment of Immunology, IMIM Hospital del Mar Research Institute, Barcelona, 
      Spain.
FAU - Pujol, Ramon M
AU  - Pujol RM
AD  - Department of Dermatology, Hospital del Mar Research Institute, Barcelona, Spain.
FAU - Gimenez-Arnau, Ana M
AU  - Gimenez-Arnau AM
AD  - DDepartment of Dermatology, Hospital del Mar Research Institute. Universitat 
      Pompeu Fabra, Barcelona, Spain. anamariagimenezarnau@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20240108
PL  - Sweden
TA  - Acta Derm Venereol
JT  - Acta dermato-venereologica
JID - 0370310
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Humans
MH  - *Urticaria, Solar
MH  - Follow-Up Studies
MH  - Omalizumab/adverse effects
MH  - *Urticaria/diagnosis/drug therapy
MH  - Immunoglobulin E
PMC - PMC10789168
COIS- AMG-A is, or recently was, a speaker and/or advisor for and/or has received 
      research funding from Almirall, Amgen, AstraZeneca, Avene, Celldex, Escient 
      Pharmaceutials, Genentech, GSK, Instituto Carlos III- FEDER, Leo Pharma, 
      Menarini, Mitsubishi Tanabe Pharma, Novartis, Sanofi-Regeneron, Servier, Thermo 
      Fisher Scientific, Uriach Pharma / Neucor, outside the submitted work. David 
      Pesque benefits from a research grant of Leo-Pharma, outside the submitted work. 
      All other authors have no conflicts of interest to declare.
EDAT- 2024/01/08 06:43
MHDA- 2024/01/09 06:41
PMCR- 2024/01/08
CRDT- 2024/01/08 05:53
PHST- 2023/11/09 00:00 [received]
PHST- 2023/11/17 00:00 [accepted]
PHST- 2024/01/09 06:41 [medline]
PHST- 2024/01/08 06:43 [pubmed]
PHST- 2024/01/08 05:53 [entrez]
PHST- 2024/01/08 00:00 [pmc-release]
AID - ActaDV-104-25576 [pii]
AID - 10.2340/actadv.v104.25576 [doi]
PST - epublish
SO  - Acta Derm Venereol. 2024 Jan 8;104:adv25576. doi: 10.2340/actadv.v104.25576.